Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Mozobil and G-CSF for Stem Cell Mobilization in Lymphoma and Myeloma
NCT03244930Phase 2Unknown
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of plerixafor in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and multiple myeloma (MM), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Primary endpoint: Harvest of at least 2 x 10^6 CD34+/kg at 5 days. Status: unknown.
02
Drugs
plerixafor
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03244930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244930.